Sliding scale regimen versus basal bolus insulin regime for hyperglycemia management in hospitalized patients with type 2 diabetes
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 January 2026
,
Page 1-7
https://doi.org/10.22037/ijmtfm.v16.50965
Abstract
Background: Since type-2 diabetes mellitus (T2DM) is becoming more common, it is crucial to implement an appropriate care plan for these patients' hyperglycemia to lower the risk of complications. While Sliding Scale Insulin (SSI) has been the traditional approach, Basal-bolus insulin (BBI) therapy is a promising strategy and is increasingly recommended. We aimed to compare the efficacy of SSI versus BBI regimens in hospitalized patients with T2DM.
Methods: The demographics, complications, and type of insulin therapy for type 2 diabetic hospitalized patients were recorded from patients’ archived documents.
Results: We observed that 59.7% of the patients were treated for SSI accompanied by macrovascular complications. While 37.8% of patients treated with BBI had macrovascular complications, the difference between the BBI & SSI groups was statistically significant. For microvascular complications, also, a statistically significant difference was detected between the BBI & SSI groups (P-value = 0.001). Only 18.6% & 17.2% of the patients developed hypoglycemia in the BBI group & SSI group, respectively. We evaluated the efficacy of both treatments on daily random blood glucose (RBG) in our patients for 1 week; a slight decrease in RBG was observed between the first & the seventh days of treatment in the SSI group. An obvious improvement was observed in the BBI, indicating that BBI was more effective at controlling RBG than SSI.
Conclusion: Our study demonstrated that BBI therapy was superior to SSI therapy in achieving ideal blood glucose levels, with fewer hypoglycemic episodes and cardiovascular events.
- Type 2 diabetes mellitus, Basal–bolus insulin, Sliding scale insulin, Hyperglycemia
How to Cite
References
[1] Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycemia in hospitalized patients. Endotext [Internet]. 2024. [DOI: 10.4158/EP-2024-00623]
[2] Alex M, Sreedharan DP, Bhandari R, Kolar R. Retrospective analysis of Sliding Scale versus Basal Bolus Insulin in the treatment of uncontrolled hyperglycemia in patients with Type 2 diabetes mellitus and infections. Int J Diabetes Dev Ctries. 2025;45(3):661–9. [DOI: 10.1007/s13410-024-01500-5]
[3] Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169–74. [DOI: 10.2337/dc12-2470]
[4] Saadoon SJ, Helmy H, Mostafa FM. Hyperglycemia Management in Critical Units and End-Stage Hospitalized Patients. Int J Med Toxicol Forensic Med. 2025;15(03):1–6. [DOI: 10.32598/ijmtfm.15.3.1]
[5] Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5. [DOI: 10.2337/dc13-0685]
[6] Migdal AL, Fortin‐Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: who can slide? J Hosp Med. 2021;16(8):462–8. [DOI: 10.12788/jhm.3638]
[7] Garber AJ, Moghissi ES, Bransome ED Jr, Clark NG, Clement S, Cobin RH, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract. 2004;10 Suppl 2:4–9. [DOI: 10.4158/EP.10.S2.4]
[8] Vellanki P, Cardona S, Galindo RJ, Urrutia MA, Pasquel FJ, Davis GM, et al. Efficacy and safety of intensive versus nonintensive supplemental insulin with a basal-bolus insulin regimen in hospitalized patients with type 2 diabetes: a randomized clinical study. Diabetes Care. 2022;45(10):2217–23. [DOI: 10.2337/dc22-0459]
[9] Aly A, Al Suleimani Y. Management of Hyperglycemia in Hospitalized Patients with Type-2 Diabetes Using Insulin Therapy. Eur J Clin Pharm. 2022;24(2):84–91. [DOI: 10.29045/14784710.2022.24.2.84]
[10] Zaman Huri H, Permalu V, Vethakkan SR. Sliding-scale versus basal-bolus insulin in the management of severe or acute hyperglycemia in type 2 diabetes patients: A retrospective study. PLoS One. 2014;9(9):e106505. [DOI: 10.1371/journal.pone.0106505]
[11] Umpierrez GE, Pasquel FJ. Management of inpatient hyperglycemia and diabetes in older adults. Diabetes Care. 2017;40(4):509–17. [DOI: 10.2337/dc16-1722]
[12] Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–61. [DOI: 10.2337/dc10-1417]
- Abstract Viewed: 36 times
- PDF Downloaded: 62 times